Imatinib Completed Phase 2 Trials for Chronic Myelomonocytic Leukemia / Dermatofibrosarcoma / Hypereosinophilic Syndromes / Systemic Mastocytosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00171912Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes